Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D Pharmaceutical TechnologyData presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.Clinical DataCardiovascularRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes. Clinical DataCardiovascularRead full story Post navigation Previous: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave CrashesNext: Viridian reports positive results from elegrobart phase 3 trial Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026